Supplementary Materials

The PDF file includes:

  • Fig. S1. Preclinical trials with PDXs and PDCs from CCAs.
  • Fig. S2. Results of drug screening of CCA PDCs and cell lines.
  • Fig. S3. Bortezomib-sensitive cell lines are susceptible to ER stress and have high rates of protein synthesis.
  • Fig. S4. PTEN-deficient CCAs are susceptible to PTEN restoration.
  • Fig. S5. PTEN suppresses proteasome gene expression in CCA cell lines and mouse models.
  • Fig. S6. PTEN regulates proteasome activity independent of NRF1 and NRF2.
  • Fig. S7. PTEN inhibits ARE transcriptional activity and proteasome activity through BACH1 and MAFF.
  • Fig. S8. BACH1 and MAFF regulate the sensitivity to bortezomib treatment.
  • Fig. S9. PTEN regulates proteasome activity and bortezomib efficacy.
  • Fig. S10. PTEN inhibits proteasome subunit gene expression and activity in prostate cancer.
  • Legends for data files S1 to S3

[Download PDF]

Other Supplementary Material for this manuscript includes the following: